AP480A - 3-Substituted indole 2-carboxylic acid derivatives. - Google Patents

3-Substituted indole 2-carboxylic acid derivatives. Download PDF

Info

Publication number
AP480A
AP480A APAP/P/1993/000524A AP9300524A AP480A AP 480 A AP480 A AP 480A AP 9300524 A AP9300524 A AP 9300524A AP 480 A AP480 A AP 480A
Authority
AP
ARIPO
Prior art keywords
compound
group
dichloroindole
formula
ethenyl
Prior art date
Application number
APAP/P/1993/000524A
Other versions
AP9300524A0 (en
Inventor
Alfredo Cugola
Giovannie Gaviraghi
Simone Giacobbe
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of AP9300524A0 publication Critical patent/AP9300524A0/en
Application granted granted Critical
Publication of AP480A publication Critical patent/AP480A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The invention relates to compounds of formula

Description

This invention relates to novel indole derivatives to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. In particular it relates to indole derivatives which are potent and specific antagonists of excitatory amino acids.
U.S. Patent No. 4960786 discloses that certain known 2-carboxylic indole derivatives are antagonists of excitatory amino acids. EP-A 0396124 also teaches that certain 2-carboxylic indole derivatives as being therapeutically effective in the treatment of CNS disorders resulting from neurotoxic damage or neurodegenerative diseases.
We have now found a novel group 2-carboxyindole derivatives that have a highly potent and specific antagonist activity at the strychnine insensitive glycine binding site located on the NMDA receptor complex.
Accordingly the present invention provides a compound of formula (I).
(.. or a salt, or metabolically labile ester thereof wherein R represents a group selected from halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, hydroxy, trifluoromethyl, trifluoromethoxy, nitro, cyano, SO2R1 or COR-j wherein R-, represents hydroxy, methoxy, or amino; m is zero or an integer 1 or 2;
A represents an ethynyl group or an optionally substituted ethenyl, or cyclopropyl group;
X represents -O- or NH;
R2 represents an aryl group and when X represents an oxygen atom R2 may also represent a hydrogen atom or an alkyl group;
The compounds represented by formula (I) can exist in more than one isomeric form. Thus when the group A in compounds of formula (I) is an optionally substituted ethenyl or optionally substituted cyclopropyl group there can exist cis and trans isomers and the invention includes all such isomers and mixtures thereof.
BAD ORIGINAL 0
For use in medicine the salts of the compounds of formula (I) will be physiologically acceptable thereof. Other salts however may be useful in the preparation of the compounds of formula (I) or physiologically acceptable salts thereof. Therefore unless otherwise stated references to salts includes both physiologically acceptable salts and non-physiologically acceptable salts of compounds of formula (I).
Suitable physiologically acceptable salts of compounds of the invention include base addition salts and where appropriate acid addition salts.
Suitable physiologically acceptable base addition salts of compounds of formula (I) include alkali metal or alkaline metal salts such as sodium, potassium,, calcium, and magnesium, and ammonium salts formed with amino acids (e.g. lysine and arginine) and organic bases (e.g. procaine, phenylbenzylamine, ethanolamine diethanolamine and N-methyl glucosamine).
It will be appreciated that the compound of formula (I) may be produced in vivo by metabolism of a suitable prodrug. Such prodrugs may be for example physiologically acceptable metabolically labile esters of compounds of the general formula (I). These may be formed by esterification, for example of any of the carboxylic acid groups in the parent compound of general formula (I) with where appropriate prior protection of any other reactive groups present in the molecule followed by deprotection if required. Examples of such metabolically labile esters include Ci.4.alkyl esters e.g. methyl or ethyl esters, substituted or unsubstituted aminoalkyl esters (e.g. aminoethyl, 2-(N,Ndiethylamino) ethyl, or 2-(4-morpholino)ethyl esters) or acyloxyalkyl esters such as, acyloxymethyl or 1-acyloxyethyl e.g. pivaloyloxymethyl, 1-pivaloyloxyethyl, acetoxymethyl, 1 - acetoxyethyl, 1-methoxy-1-methyl-ethylcarbonyloxyethyl, 1benzoyloxyethyl, isopropoxycarbonyloxymethyl, 1 -isopropoxycarbonyloxyethyl, cyclohexylcarbonyloxymethyl, 1-cyclohexylcarbonyloxyethyl ester, cyclohexyloxycarbonyloxymethyl, 1-cyclohexyloxycarbonyloxyethyl, 1-(4tetrahydropyranyloxycarbonyloxyethyl) or 1 -(4tetrahydropyranylcarbonyloxyethyl.
Preferred metabolically labile esters of compounds of formula (I) include C-^alkyl esters more particular methyl or ethyl, aminoalkyl esters more particular 2-(4'-morpholino)ethyl, or acyloxyalkyl esters e.g. acetoxymethyl pivaloxymethyl, 1-cyclohexyloxycarbonyloxyethyl or 1-(4tetrahydropyrany loxycarbonyloxy) ethyl.
BAD ORIGINAL
The compounds of formula (I) and salts and metabolically labile esters thereof may from solvates e.g. hydrates and the invention includes such solvates.
In the compounds of formula (I) the group R may be at any of the four possible positions on the fused benzene ring and when m is 2 the two R groups may be the same or different.
The term alkyl as used herein as a group or part of a group refers to a straight or branched chain alkyl group containing from 1 to 4 carbon atom examples of such groups include methyl, ethyl propyl, isopropyl, n-butyl, isobutyl, secondary butyl or tertiary butyl.
The term halogen refers to a fluorine, chlorine or bromine atom.
The term optionally substituted ethenyl means an ethenyl group optionally substituted by 1 or 2 alkyl groups e.g. methyl groups and includes both the cis and trans conformations. Examples of such groups include ethenyl, 1 -methylethenyl, 2-methylethenyl and/or 1,2-dimethylethenyl.
The term optionally substituted cyclopropyl means a cyclopropyl group optionally substituted by 1, 2 or 3 alkyl groups e.g. methyl groups.
For the group R2 the term aryl means an optionally substituted phenyl group, or a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains 1 or 2 heteroatoms selected from oxygen, sulphur or nitrogen and the 6 membered heteroaryl group contains 1 or 2 nitrogen atoms. Examples of suitable heteroaryl groups include furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl and pyrimidinyl.
The term substituted phenyl refers to a phenyl group substituted with up 3 substituents selected from halogen, C-j. 4alkyl, C-j ^alkoxy, amino, alkylamino, dialkylamino, trifluoromethyl, trifluoromethoxy, hydroxy, cyano, nitro, amino, SO2R1 or COR-j when there is more than one substitutent present these may be the same or different.
A preferred class of compounds of formula (I) are those wherein R is chlorine, m is 1 or 2 and R is at the 4 and/or 6 position, and more particularly m is 2.
When A is an optionally substituted ethenyl group it is preferably in the E conformation.
When the group R2 is a substituted phenyl group the phenyl moiety is preferably substituted by one or more groups selected from alkoxy, alkyl,
BAD ORIGINAL amino, alkylamine, dialkylamino, fluoro, chloro, hydroxy, nitro, trifluoromethyl or CORi, wherein R-j is hydroxy or methoxy.
A preferred class of compound of formula (I) are those wherein R2 is phenyl or phenyl substituted by one or two groups selected from fluorine trifluoromethyl, alkyl e.g. methyl or isopropyl, hydroxy, alkoxy or nitro or more especially R2 is phenyl.
A further preferred class of compounds of formula (I) are those wherein X is NH.
( A preferred group of compounds of formula (I) are those wherein R is
- 10 chlorine and m is 1 or more preferably 2, X is NH or O and R2 is an optionally substituted phenyl group. From within this group particularly preferred compounds include those wherein X is NH .
A further preferred group of compounds of formula (I) are those wherein A represents an optionally substituted cyclopropyl group or more particularly an ethynyl group or a substituted ethenyl group such as 1 methlyethenyl. From within this group particularly preferred compounds includes those wherein X is NH and R2 is optionally substituted phenyl, and more especially phenyl.
For the compounds of formula (I) wherein A respresents an unsubstituted ethenyl group, preferred compounds of the invention include those wherein X is NH, R2 is optionally substituted phenyl and the group A is in the trans (E) configuration. From within this preferred groups of compounds, (' particularly preferred compounds include those wherein R2 is a phenyl group substituted by one or two groups selected from fluorine, trifluoromethyl, methyl, isopropyl, hydroxy, alkoxy e.g. methoxy or ethoxy, or nitro.
An especailly preferred compound of the invention due to its particularly potent and selective action at the strychinine insensitive gylcine binding site, coupled with very advantageous bioavailability is (E)-3-[2(phenylcarbamoyl)ethenyl]-4,6,dichloroindole-2-carboxylic acid, physiologically acceptable salts, and metabolically labile esters thereof. Preferred salts of this compound include the potassium and more especially the sodium salt thereof. Preferred metabolically labile esters of this compound include the ethyl and 2(4-morpholino)ethyl esters thereof.
Further particularly preferred compounds include
c r 10 (
C
3-[2-(phenylcarbamoyl)ethynyl]-4,6-dichloroindole-2-carboxylic acid, physiologically acceptable salts and metabolically labile esters thereof;
3-[2-(phenylcarbamoyl)propenyl]-4,6-dichloroindole-2-carboxylic acid, physiologically acceptable salts and metabolically labile esters thereof;
Other particularly preferred compounds include: (E)-3-[2-(4-ethoxyphenylcarbamoyl)ethenyl)-4,6-dichloroindole-2- carboxylic acid;
(E)-3-(2-(2-hydroxy-5-nitrophenylcarbamoyl)ethenyl)-4,6-dichloroindole-2 carboxylic acid;
(E)-3-[2-(2-methyl-4-methoxyphenylcarbamoyl)ethenyl)-4,6-dichloroindole-2carboxylic acid;
(E)-3-[2-(2-isopropylphenylcarbamoyl)ethenyl)-4,6-dichloroindole -2- carboxylic acid;
(E)-3-[2-(2,4-difluorophenylcarbamoyl)ethenyl)-4,6- dichloroindole-2-carboxylic acid;
(E)-3-[2-(3,4-dimethoxyphenylcarbamoyl)ethenyl)-4,6-dichloroindole-2-carboxyl ic acid;
and physiologically acceptable salts thereof e.g. sodium or potassium salts and metabolically labile esters thereof.
The compounds of formula (I) and or physiologically acceptable salts thereof are excitatory amino acid antagonists. More particularly they are potent antagonists at the strychnine insensitive glycine binding site associated with the NMDA receptor complex. As such they are potent antagonists of the NMDA receptor complex. Moreover the compounds of the invention exhibit an advantageous profile of activity including good bioavailibility. These compounds are therefore useful in the treatment or prevention of neurotoxic damage or neurodegenerative diseases. Thus the compounds are useful for the treatment of neurotoxic injury which follows cerebral stroke, thromboembolic stroke, hemorrhagic stroke, cerebral ischemia, cerebral vasospam, hypoglycemia, anaesia, hypoxia, anoxia, perinatal asphyxia cardiac arrest. The compounds are useful in the treatment of chronic neurodegenerative diseases such as; Huntingdon's disease, Alzheimer's senile dementia, amyotrophic lateral sclerosis, Glutaric Acidaemia type, multi-infarct dementia, status epilecticus, contusive injuries (e.g. spinal cord injury), viral infection induced neurodengeration , (e.g. AIDS, encephalopaties), Down syndrome, epilepsy,
BAD ORIGINAL £ (' ( 10 (' ( 10 (
( schizophrenia, depression, anxiety, pain, neurogenic bladder, irritative bladder disturbances, drug dependency, including withdrawal symptoms from alcohol, cocaine, opiates, nicotine, benzodiazepine.
The potent and selective action of the compound of the invention at the strychnine- insensitive glycine binding site present on the NMDA receptor complex may be readily determined using conventional test procedures. Thus the ability to bind at the strychnine insensitive glycine binding site was determined using the procedure of Kishimoto H et al. J Neurochem 1981, 37 1015-1024. The selectivity of the action of compounds of the invention for the strychnine insensitive glycine site was confirmed in studies at other ionotropic known excitatory amino acid receptors. Thus compound of the invention were found to show little or no affinity for the kainic acid (kainate) receptor, a-amino3-hydroxy-5-methyl-4-isoxazole-proprionic acid (AMPA) receptor or at the NMDA binding site.
Compounds of the invention have also been found to inhibit NMDA induced convulsions in mice using the procedure Chiamulera C et al. Psychopharmacology (1990) 102, 551-552.
The neuroprotective activity of compounds of the invention has also been demonstrated in the middle cerebral artery occulsion preparation in mice, using the procedure described by Chiamulera C et al. European Journal of Pharmacology 216 (1992) 335-336. The compound was active when administered either pre-ischemia or post ischemia.
The invention therefore provides for the use of a compound of formula (I) and or physiologically acceptable salt or metabolically labile ester thereof for use in therapy and in particular use as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.
The invention also provides for the use of a compound of formula (I) and/or a physiologically acceptable salt or metabolically labile ester thereof for the manufacture of a medicament for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.
According to a further aspect the invention also provides for a method for antagonising the effects of excitatory amino acids upon the NMDA receptor complex, comprising administering to a patient in need thereof an antagonistic amount of a compound of formula (I) and/or a physiologically acceptable salt or metabolically labile ester thereof.
r 10
C (
It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of established diseases or symptoms.
It will further be appreciated that the amount of a compound of the invention required for use in treatment will vary with the nature of the condition being treated the route of administration and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician. In general however doses employed for adult human treatment will typically be in the range of 2 to 800mg per day, dependent upon the route of administration.
Thus for parenteral administration a daily dose will typically be in the range 20-1 OOmg preferably 60-80mg per day. For oral administration a daily dose will typically be within the range 200-800mg e.g. 400-600mg per day.
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.
While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical formulation.
The invention thus further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt or metabilcially labile ester thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The compositions of the invention include those in a form especially formulated for oral, buccal, parenteral, inhalation or insufflation, implant, or rectal administration. Parenteral administration is preferred.
Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example, syrup, accacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone; fillers, for example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch or sodium starch glycollate, or wetting agents such as sodium lauryl sulphate. The tablets
BAD ORIGINAL &
may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; and preservatives, for example, methyl or propyl phydroxybenzoates or ascorbic acid. The compositions may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.
The composition according to the invention may be formulated for parenteral administration by injection or continuous infusion. Formulations for injection may be presented in unit dose form in ampoules, or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
For administration by inhalation the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs, with the use of a suitable propellant, such as dichlorodifluoromethane, tirchlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide or other suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide or other suitable gas, or from a nebuliser. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.
Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable carrier such as lactose or starch. The powder composition may be presented in unit dosage form in for example capsules or cartridges of e.g. gelatin, or blister packs from which the powder may be administered with the aid of an inhaler or insufflator.
The composition according to the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
The compositions according to the invention may contain between 0.1 - 99% of the active ingredient, conveniently from 30- 95% for tablets and capsules and 3-50% for liquid preparations.
Compounds of general formula (I) and salts thereof may be prepared by the general methods outlined hereinafter. In the following description, the groups R, R-ι and R2 are as defined for the compounds of formula (I) unless otherwise stated.
Compounds of formula (I) wherein A is an optionally substituted ethenyl group may be prepared from compound (II) in which R, m and n have the means given above, R3 is a carboxyl protecting group, and R4 is a hydrogen atom or a Chalky I group.
K by reaction with an appropriate phosphorus ylide capable of converting the group CR4O into the group ACOXR2 wherein X and R2 have the meanings defined above for formula (I) followed where necessary or desired by removal of the carboxyl protecting group.
Suitable carboxyl protecting groups include allyl, alkyl, trichloroalkyl, trialkylsilylalkyl or arymethyl groups such as benzyl, nitrobenzyl or trityl.
In one embodiment of this process the reaction may be carried using a phosphorus ylide of formula (III)
(R5)3P=CHCO»% (III) wherein R5 is an alkyl or phenyl group, and X and R3 have the meanings 5 defined above.
The reaction is carried out in aprotic solvent such as acetonitrile or an ether such as 1,4-dioxane and preferably with heating e.g. 40-120°.
In a further embodiment of the process the reaction is carried out using a phosphorus ytide of formula (IV) (^0)^=000)^
Re wherein Rg represents hydrogen or C-j_4alkyl.
R7 represents Chalky I and X and R3 have the meanings defined.
The reaction is carried out in an aprotic solvent such as tetrahydrofuran and optionally with heating.
Compounds of formula (I) wherein A is an optionally substituted cyclopropyl group may be prepared by treating the olefin (V)
wherein R, R3, R4, R6, and m have the meanings defined above and Rg is a hydrogen atom or a Chalky I group, with the diazo derivative (VI), wherein the groups X and R2 are as defined above, followed where necessary or desirable by removal of the carboxyl protecting group R3. The reaction is carried out in a solvent such as 1,2-dimethoxyethane and in the presence of a Rhodium (11) catalyst such as rhodium acetate or pivalate.
Compounds of formula (I) wherein A is an ethynyl group may be prepared by reaction of the alkyne of formula (VII)
(VII) .caoooxRj
CO2CH3 f
(' (
( 20 f
c (
( 20 wherein R, m X and R2 have the meanings defined in formula (I) and Rg represents the group (CH3)3SiCH2CH2OCH2-, with hydrochloric acid in ethanol, followed by reaction with a suitable base such as lithum hydroxide.
Compounds of formula (I) or protected derivatives thereof may be converted into other compounds of the invention.
Thus compounds of formula (I) wherein A is an unsubstituted ethenyl group with the cis configuration may be prepared from the corresponding compound of formula (I) wherein A is ethynyl by reduction using hydrogen and palladium on a calcium carbonate/lead oxide support as catalyst.
Compounds of formula (I) wherein A is an optionally substituted cyclopropyl group may be prepared by reaction a compound of formula (I) wherein A is an optionally substituted ethenyl group, or a protected derivative thereof, e.g. an ester thereof with diazomethane in the presence of palladium acetate, followed where necessary or desired by the removal of any protecting group. The reaction is carried out in an aprotic solvent e.g. dichloromethane and/or an ether and preferably at a temperature within the range 0-20θ.
In any of the above reactions the carboxyl protecting group R3 may be removed by conventional procedures known for removing such groups. Thus the group R3 may be removed by hydrolysis using an alkali metal hydroxide e.g. lithium hydroxide in a solvent such as ethanol, followed where desired or necessary by that addition of a suitable acid e.g. hydrochloric acid to give the corresponding free carboxylic acid.
Physiologically acceptable salts of compounds of formula (I) may be prepared by treating the acid with the appropriate base e.g. alkali or alkaline earth metal hydroxide in an appropriate solvent such as an alkanol e.g. methanol.
Metabolically labile esters of compounds of formula (I) may be prepared by esterification of the carboxylic acid group or a salt thereof or by trans esterfication using conventional procedures. Thus for example acyloxyalkyl esters may be prepared by reacting the free carboxylic acid or a salt thereof with the appropriate acyloxylalkyl halide in a suitable solvent such as dimethylformamide. For the esterifcation of the free carboxyl group this reaction is preferably carried out in the presence of a quaternary ammonium halide such as tetrabutylammonium chloride or benzyltriethylammonium chloride.
Aminoalkyl esters may be prepared by transesterfication of a corresponding alkyl ester e.g. methyl or ethyl ester by reaction with the corresponding aminoalkanol at an elevated temperature e.g. 50-150°.
Compounds of formula (II) wherein R3 is a carboxyl protecting group,
R4 is hydrogen may be prepared by treating the corresponding indole (VIII).
wherein R and m are as defined in formula (I) with N- methylformanilide and phosphorous oxychloride in a solvent such as 1,2-dichloroethane.
Compounds of formula (II) wherein R3 is a carboxyl protecting group, R4 is alkyl and n is zero may be prepared by treating the indole (VIII) with the amide (CH3)2NCOR4 and phosphorous oxychloride in a suitable solvent.
Compounds of formula (V) may be prepared by treating the corresponding compound of formula (II) with a reagent capable of introducing the group CR4=CRgRg.
Thus reaction of a compound of formula (II) witn the triphenylphospine derivative Ph3P+CH2Rg Br in the presence of a suitable base such as butyl lithum and in an aprotic solvent will give the corresponding compound of formula (V) wherein Rg is hydrogen.
Compounds of formula (V) wherein R4 represents hydrogen and Rg and Rq independently represent CMalkyl may be prepared by treating a compound of formula (II) in which R4 represents hydrogen with the disubstituted ylide RgRg· C-P+Ph3 in a suitable solvent such as Ν,Ν-dimethylformamide. Preferably the disubstituted ylide is prepared in situ by treating the trimethylsilyl derivative (CH3)3SiCRgR8P+Ph3 Y wherein Y is an anion, with cesium fluoride. The trimethylsilyl derivative may be prepared by the method of Bestmann and Bomhard. Angew Chem. Int. Ed. Eng. 21 (1982) NO. 7 pages 545-546. Compounds of formula (V) wherein R4, Rg and Rg are each an alkyl group may be prepared from the corresponding compound of formula (II) by reaction with the phenylsulphonate (PhSC^CHRgRg). The reaction may be carried out using
BAD ORIGINAL ft the general reaction procedure described by Julia and Paris. Tetrahedron Letters No. 49, 4833-4836 1973.
The compounds of formula (VII) may be prepared by reaction of the bromo acid (IX)
(IX) with the appropriate isocyanate R2NCO or chloroformate R2OCOCI in the presence of a suitable base such as t-butyl lithium and, in an aprotic solvent such as tetrahydrofuran and subsequent reaction of the crude reaction product with trimethylsilyldiazemethane ((CH3)3SiCHN2). The bromo (IX) acid may be prepared from the indole (II) wherein R4 is hydrogen by the following reaction sequence.
BAD ORIGINAL ft
The compounds of formula (IX) may be prepared by alkaline hydrolysis of the corresponding ester (X). The ester (X) may be prepared from the corresponding dibromothene (XI) by reaction with a suitable base such as lithium bis-trimethylsilylamide in a solvent such as an ether e.g. tetrahydrofuran. The dibromoethene (XI) may be prepared from the corresponding aldehyde (XII) by reaction with triphenylphospine and carbon tetrabromide in a solvent such as dichloromethane. The N-protected indole (XII) may be prepared from the indole (II; R4=H) by reaction with trimethylsilylethoxymethylchloride in the presence of a base such as sodium bis-trimethylsilylamide in a polar aprotic solvent such as dimethylformamide.
BAD ORIGINAL ft
The indoles of formula (VIII) are either known compounds or may be prepared by analogus methods to these described for the known compounds.
In order that the invention may be more fully understood the following examples are given by way of illustration only.
In the Intermediates and Examples unless otherwise stated:
Melting points (m.p.) were determined on a Gallenkamp m.p. apparatus and are uncorrected .All temperature refer to C.lnfrared spectra were mesured on a FT-IR instrument. Proton Magnetic Resonance (1H-NMR) spetra were recorded at 300 MHz, chemical shifts are reported in ppm downfield (d) from Me4Si, used as internal standard , and are assigned as singlets (s), doublets (d), doublets of doublets (dd), triplets (t), quartets (q) or multiplets (m). Colum chromathography was carrier out over silica gel (Merck AG Darmstaadt, Germany). The following abbreviations are used in text: EA = ethyl acetate, CH = cyclohexane, DCM = dichlormethane, DBU = 1,8 diazabicyclo [5.4.0]undec7-ene. DMF = NM -dimethylformamide, T H F = tetrahydrofuran, UOH.H2 lithium hydroxide monohydrate. Tic refers to a thin layer chromatography on silica plates. Solution were dried over anhydrous sodium sulphate.
Intermediate I
Ethyl 4.6-dichloroindole-2-carboxylate
To a solution of ethyl pyruvate (2.05 ml), in absolute ethanol (38 ml), concentrated sulphuric acid (0.5 ml) was added slowly under vigorous stirring. The resulting mixture was stirred at 23 for 10 minutes, then 3,5dichlorophenylhydrazine hydrochloride (4g) was added portionwise. The mixture was heated to reflux for 4 hours, cooled to 23°, poured into cold water (500 ml) and extracted with diethyl ether (3 X 300 ml). The organic layers were separated and dried. The solvent was evaporated under reduced pressure to give the 2-(3,5-dichlorophenylhydrazone) propionic acid ethyl ester as yellow solid (5g; tic DCM, Rf=0.79, 0.47) in E and Z isomers mixture. The solid was added to polyphosphoric acid (20 g) under stirring and the mixture was heated at 45θ for 20 minutes to give a brown product which was crystallized by 95% ethanol (300 ml) to obtain the title compound as a yellow-brown solid (3.3 g;m.p.180°; Tic DCM, Rf=0.54). IR(CDCl3) Vmax(cnr1)3440(NH), 17721709(C=O).
BAD ORIGINAL
Intermediate 2
Ethyl 3-formyl-4.6-dichloroindole-2-carboxylate
A solution of N-methyl formanilide (5.19 g) and phosporous oxychloride (5.53g) was stirred at 23° for 15 minutes. 1,2- Dichloroethane (60ml) and intermediate I (6g) were added and the resulting suspension was stirred at 80° for 6 hours.The reaction mixture was poured into a 50% aqueous solution of sodium acetate (300 ml) to give , by filtration, the title compound as a yellow solid (4.1 g; tic EA/CH:4/6, Rf=0.4).
Intermediate 3
Ethyl 3-formyl-1-(2-trimethvlsilvl-ethoxvmethvl)-4.6-dichloroindole-2-carboxylate acid
To a cooled solution of intermediate (2) (700 mg) in dry DMF (20ml) at 0° was added lithium bis-trimethylsilylamide (3.7 ml), 1M solution) in THF. The mixture was stirred for 15 minutes at 0°, then tri-methylsilylethoxymethyl chloride (0.817g) was added. After one hour the resulting mixture was poured into water (25 ml) and extracted with ethyl acetate (3 x 20 ml). The combined organic layers were dried and concentrated under vacuum. The residue was purified by chromatography on silica gel to afford the title compound (950 mg) as a pale yellow solid.
Rf = 0.3EA/CH: 1.9.
Intermediate 4
Ethvl 3-(2.2-dibromovinvl)-1-(trimethylsilyl-ethoxymethvn-4.6-dichloroindole-2carboxvlate
Intermediate 3 (300 mg) was dissolved in dry dichloromethane (7 ml) and the solution was cooled to -15° with an ice/salt bath. Then, triphenylphosphine (1.14 g) and carbon tetrabromide (719 ml) were added and the resulting solution was stirred for 1.5 hrs, while the temperature was gradually increased to o°. Saturated NH4CI (20 ml) was then added, the two phases separated and the water phase extracted twice with dichloromethane. The combined organic phase was dried, concentrated and the obtained residue was passed through a silica gel pad (CH/EA:9/1) to give the title compound (390 mg) as a yellow oil.
Rf = 0.62 CH/EA: 9/1
BAD ORIGINAL &
Intermediate 5
Ethyl 3-bromoethvnvl-1-i2-trimethvlsilvlethoxvmethy0-4.6-dichlorindole-2carboxvlate
Intermediate 4 was dissolved in dry THF (50 ml) and the solution was cooled to 0° in an ice/water bath. Lithium bis trimethylsilylamide (7.6 ml, 1.0 M sol. in THF) was slowly added from a syringe, the mixture stirred at 0° for 30 minutes and then quenched with saturated NH4CI (20 ml). Ethyl acetate was added, the two phases separated and the organic layer washed with 1N hydrochloric acid, dried and concentrated to dryness. The crude product was purified by column chromatography to give the title compound (2.9 g) as a yellow oil.
Rf = 0.35 CH/EA: 95/5
Intermediate 6
3-Bromoethvnyl-1-(2-trimethvlsilvlethoxvmethvl)-4.6-dichloroindole-2-carboxvlic acid
Intermediate 5 (2.9 g) was dissolved in ethanol 95% (40 ml), then LiOH-H2O was added and the solution was stirred overnight at 80°. The reaction mixture was then concentrated to dryness and the resulting residue washed with 1N HCI. After filtration the obtained solid was washed with water and dried over P2O5 to yield the title compound (2.6 g) as a white solid.
IR (Nujol) (cm·1) 1676(0=0), 1600(C=C) 1- H-NMR(DMSO) 14.00(s), 7.90(d), 7.38(d), 5.92(s), 3.41 (t), 0.76(t), -0.13(s)
Intermediate 7
Methyl 3-phenylcarbamovlethvnvl-1-(2-trimethvlsilylethoxvmethyD-4.6dichlorooindole-2-carboxylate
Intermediate 6 (454 mg) was dissolved in dry THF (15 ml) and the solution cooled to -78°. A solution of t-butyl-lithium (1.3 ml, 1.7M in hexane) was slowly added and the reaction mixture was stirred for 2 hrs. Phenylisocyanate (0.12 ml) was then, added and the mixture was gradually warmed to room temperature and stirred for 3 hrs. The reaction was quenched with saturated NH4CI and extracted with ethyl acetate. The combined organic phases were washed with 1N HCI, water and brine, dried and concentrated to dryness. The crude product was then, solubilized in dichloromethane (8 ml) and methanol (2
BAD ORIGINAL ft ml) and treated at room temperature with Me3SiCHN2 (1.2 ml, 1.0M sol. in hexane). After 30 min of stirring, the solution was concentrate to dryness and the crude material was purifyed by flash chromatography (CH/EA:85/5) to give the title compound (230 mg,) as a yellow solid.
Intermediate 8 (El-Ethvl 3-f2-(phenvlcarbamovl)ethenvn-1-(2-trimethvlsilylethoxvmethvh-4.6dichloroindole-2-carboxvlate
To a cooled (o°) solution of (E)-Ethyl-3-[2-(phenylcarbamoyl)ethenyl]-4,6dichloroindole-2-carboxylate (300 mg) in dry DMF (25 ml) a solution of sodium bis-(trimethylsilyl)amide (1M;0.0814 ml) was added dropwise. The resulting mixture was stirred at room temperature for 30 minutes then cooled to 0°. Trimethylsilylethoxymethylchloride (185 mg) was added, and the reaction was stirred for one hour at room temperature. The resulting solution was poured in H2O (20 ml) and extracted with diethylether (15 ml x 3). The organic layers were dried, concentrated under vacuum and the product isolated by chromatography on silica gel(CH/EA:83/15) to give the title compound (311 mg). Rf = 0.35 CH/EA:85/15
Intermediate 9
Ethyl 3-f(2-phenylcarbamoyl)-propenyn-1-(2-trimethylsilvlethoxvmethyD-4.6dichloroindole-2-carboxvlate
Ρ,Ρ-Diethyl 2-phosphono-propananilide (644mg) was dissovled in anhydrous DMF (10ml) and the resulting solution cooled to 0® and treated with LiN(Me3Si)2 (2.3ml of a 1.0M solution in THF) for 1.5 hour. Intermediate 3 (784mg), separately dissolved in dry DMF (8ml) was added to it and sitrring continued overnight. The reaction was quenched by pouring it into 50ml of saturated NH4CI; the aqueous phase was then extracted with ethyl acetate and the organic layer washed with 1N hydrochloric acid, water and brine, dried, filtered and concentrated. Final purification by column chromatography yielded the title compound (660mg) as an off-white solid.
Rf=0.35, CH/EA 8.5/1.5
Example 1A (El Ethyl-3-f2-(phenvlcarbamovflethenvn-4.6-dichloroindole-2- carboxylate
DBU (319mg) was added to a stirred suspension of phenylcarbamoymethyl triphenylphosphoniumbromide (1g) in acetonitrile (10ml) at under nitrogen. Stirring was continued at 0° for 15 minutes then intermediate 2 (680 mg) was added and the mixture refluxed for 6 hours. After dilution with dichloromethane (15ml), the formed precipitate was collected by filtration giving the title compound (380 mg ;tlc EA/CH :3/7, Rf=0.5) as a white solid.
IR(Nujol) Vmax(cnrr1)3305-3288(NH), 1678-1662(0=0), 1627-1601(0=0). 1HNMR (DMSO) 12.61 (s),10.20 (s), 8.27(d), 7.73(d), 7.52(d), 7.36- 7.30(m), 7.06(m), 6.77(d), 4.39 (q), 1.36(t).
Example 1B (E)Ethvl 3-[2-(4-trifluoromethylohenylcarbamoyl)ethenvll-4.6-dichloroindole-2carboxvlate
To a stirred suspension of 4-(trifluoromethyl)phenylcarbamoylmethyltriphenylphosphonium chloride (0.99 g) in acetonitrile (10 ml) at 0° under nitrogen, DBU (0.3g) was added. Stirring was continued at 0° for 25 minutes then intermediate 2 (0.56 g) was added and the mixture was refluxed for 8 h. After dilution with dichloromethane (20ml), the formed precipitate was collected by filtration giving the title compound (0.6g;) tic EA/CH:4/6 Rf=0.49) as a white solid.
IR(Nujol) Vmax(cm-1) 3310(NH),1676(0=0),1632,1612(0=0).
Example 1C (EtEthvI 3-r2-(2-isopropylphenyl)carbamoylethenvn-4.6-dichloroindole-2carboxvlate
To a stirred suspension of (2-isopropylphenyl)carbamoylphenylmethyltriphenylphosphonium chloride (0.83g) in acetonitrile (10 ml) at 0° under nitrogen, DBU was added.Stirring was continued at Οθ for 20 minutes then intermediate 2 (0.5g) was added and the mixture refluxed for 4 h. After dilution with dichloromethane (20ml) the formed precipitate was collected by filtration giving the title compound (340 mg; tic EA/CH:4/6 Rf = 0.53) as a white solid.
IR(Nujol)Vmax(cm'1)3304(NH)l 1676,1659(0=0).
Example 1D
BAD ORIGINAL ft (E) Ethvl 3-f2-(2-nitroohenvlcarbamoyl)ethenyl1-4.6-dichloroindole-2-carb oxvlate
To a stirred suspension of (2-nitrophenyl)carbamoylmethyltriphenylphosphonium chloride (0.75g) in acetonitrile (10 ml) at Οθ under nitrogen, DBU (238mg) was added. Stirring was continued at 0° for 20 minutes then intermediate 2 (0.45g) was added and the mixture refluxed for 4 h. After dilution with dichloromethane (20ml) the formed precipitate was collected by filtration giving the title compound (420 mg; tic EA/CH:4/6 Rf = 0.55) as a yellow solid.
IR(Nujol) Vmax(cm-1) 3348-3308(NH), 1672(C=O), 1607-1590(0=0), 15561346(NO2).
Example 1E (E) Ethyl 3-f2-(2-methvl-4-methoxvphenvlaminocarbonvl)ethenvn-4.6dichloroindole- 2-carboxvlate
To a suspension of (2-methyl-4-methoxyphenyl)aminocarbonylmethyltriphenylphosphonium chloride (0.998 g) in acetonitrile (15 ml) at 0° under nitrogen, DBU (0.32 g) was added. Stirring was continued at 0° for 25 minutes then intermediate 2 (0.6 g) was added and the mixture was refluxed for 3 hours. After dilution with dichloromethane (20 ml), the formed precipitate was collected by filtration giving the title compound (0.57 g; tic EA/CH:4/6 Rf=0.34) as an offwhite solid.
IR(Nujol)Vmax(crrr1)3302-3246(NH), 1678-1659(0=0), 1624(0=0).
Example 1F (E) Ethyl 3-f2-(2-hvdroxyphenvlaminocarbonyl)ethenyl1-4.6-dichloroindol e-2carboxvlate
To a suspension of (2-hydroxyphenyl)aminocarbonylmethyltriphenylphosphonium chloride (0.94 g) in acetonitrile (15 ml) at 0°C under nitrogen, DBU (0.32 g) was added. Stirring was continued at 0° for 25 minutes then intermediate 2 (0.6 g) was added and the mixture was stirred for 24 h at room temperature. The suspension was evaporated to dryness and the residue purified by flash- chromatography(EA/CH:3/7 then 4/6) giving the title compound (0.37 g; tic EA/CH:4/6 Rf=0.39) as a beige solid.
IR(Nujol)Vmax(cm-1)3317-3290(NH), 1678-1655(0=0), 1618(C=C).
BAD ORIGINAL ft
Example 1G (E) Ethvl3-f2-(3.4-dimethoxvphenvlaminocarbonvl)ethenvl1-4.6-dichloroindole-2carboxvlate
To a suspension of (3,4-dimethoxyphenyl)aminocarbonylmethyl5 triphenylphosphonium chloride (0.69 g) in acetonitrile (10 ml) at 0° under nitrogen, DBU (0.21 g) was added. Stirring was continued at 0° for 25 minutes then intermediate 2 (0.4 g) was added and the mixture was stirred overnight at room temperature then refluxed for 3 hours. After dilution with dichloromethane (20 ml), the formed precipitate was collected by filtration giving the title compound (0.457 g; tic EA/CH:4/6 Rf = 0.20) as a yellow solid.
IR(Nujol)V max(cm-1)3317-3254(NH), 1678(0=0), 1620-1600(0=0).
Example 1H (E) Ethyl 3-f2-f4-ethoxyphenvlaminocarbonyl)ethenvl1-4.6-dichloroindole-215 carboxvlate
To a suspension of (4-ethoxyphenyl)aminocarbonylmethyl· triphenylphosphonium chloride (0.67 g) in acetronitrile (10 ml) at 0° under nitrogen, DBU (0.21 g) was added. Stirring was continued at 0° for 25 minutes then intermediate 2 (0.6 g) was added and the mixture was refluxed for 28 hours. After dilution with dichloromethane (20 ml), the formed precipitate was collected by filtration giving the title compound) (0.265 g; tic EA/CH:4/6 Rf =
0.41) as a light yellow solid.
(' IR(Nujol)Vmax(cm-1)3321-3260(NH), 1676(0=0), 1622(0=0).
Example 11 (E) Ethyl 3-i2-(2.4-difluorophenvlaminocarbonvl)ethenvn-4.6-dichloroindole-2carboxvlate
To a suspension of (2.4-difluorophenyl)aminocarbonylmethyltriphenylphosphonuim chloride (0.655 g) in acetonitrile (10 ml) at 08 under nitrogen, DBU (0.21 g) was added. Stirring was continued at 0°C for 25 minutes then intemediate 2 (0.4g) was added and the mixture was refluxed for 26 hours. After dilution with dichloromethane (20 ml), the formed precipitate was collected by filtration giving the title compound (0 42 g; tic EA/CH:4/6 Rf=0.54) as a light yellow solid.
IR(Nujol)Vmax(cm-1)3298(NH), 1678-1661(0=0), 1624(0=0).
BAD ORIGINAL ft
Example 1J (E) Ethyl 3-f2-(2-fluoro-5-nitrophenvlaminocarbonyl)ethenvl1-4.6-dichloroindole2-carboxvlate
To a suspension of (2-fluoro-4-nitrophenyl)aminocarbonylmethyltriphenylphosphonium chloride (0.52 g) in acetonitrile (10 mi) at 0° under nitrogen, DBU (0.16 g) was added. Stirring was continued at 0° for 25 minutes then intermediate 2 (0.3 g) was added and the mixture was refluxed for 18 hours. After dilution with dichloromethane (20 ml), the formed precipitate was collected by filtration giving the title compound (0.34 g; tic EA/CH:4/6 Rf = 0.41) as a beige solid.
IR(Nujol)nmax(cm'1)3300(NH), 1680-1666(0=0), 1545-1377(NO2)
Example 2A (E)342-(Phenvlcarbamovl)ethenvl1-4.6-dichloroindole-2-carboxvlic acid
To a solution of Example 1A (250mg) in ethanol (2.5ml), lithium hydroxide (104mg) was added at 23°. The reaction was stirred at 50° for 6 hours then the solvent was evaporated and the residue dissolved in water (5 ml). The aqueous layer was acidified with 1N hydrocloric acid until a white solid precipitated. The latter was collected by filtration and dried to give the title compound as a white solid (230 mg).
IR(nujol) Vmax(cm-1) 3402-3281-3192 (ΟΗ,ΝΗ), 1661(0=0),1607-1579 (C=C). 1H-NMR (DMSO) 12.4 (s), 10.1(s), 8.50(d), 7.74(d), 7.48(s), 7.27(t), 7.16(s), 7.11(d), 6.99(f).
Using the same, general, procedure the following compounds were prepared:
Example 2B (E)3-f2-(Trifluoromethvlphenvlcarbamovl)ethenyn-4.6- dichloroindole-2carboxvlic acid
Starting from Example 1B (585 mg), the title compound was obtained as a light brown solid (520 mg).
IR(nujol) Vmax(cnrr1) 3430-3000(NH,OH), 1700-1678(0=0), 1636-1614(0=0). 1H-NMR (DMSO) 14-13.5(s), 12.55(s), 10.54(s), 8.37(d), 7.91(d), 7.67(d), 7.48(d), 7.30(d), 6.86(d).
BAD ORIGINAL $
Example 2C (E)3-f2-(2-lsopropylphenvlcarbamovl)ethenvn-4.6-dichloroindole-2- carboxylic acid, dilithium salt
Starting from Example 1C (317 mg), the title compound was obtained as a light brown solid (268 mg).
IR(nujol) Vmax(cm-1) 3661 (NH,OH), 1610(C=O).
1H-NMR (DMSO) 12.1(s), 9.39(s), 8.57(d), 7.57(s), 7.38-7.28(m), 7.28-7.10(m), { 3.25(m), 1.15(d).
r 10
Example 2D (E)3-f2-(2-Nitrophenylcarbamoyl)ethenyn-4.6-dichloroindole-2- carboxylic acid
Starting from Example 1D (440 mg), the title compound was obtained as a yellow solid (290 mg).
IR(nujol) Vmax(cm'1) 3234(NH,OH), 1684-1636(C=O), 1639(C=C). 1HNMR (DMSO) 12.2(s), 10.51 (s), 8.59(d), 7.95(dd), 7.81 (dd), 7.69(m), 7.48(d), 7.38-7.28(m), 7.20(d).
Example 2E (E) 3-f2-(2-Methvl-4-methoxyphenvlaminocarbonvl)ethenyl1-4.6-dich loroindole2- carboxylic acid
Starting from Example 1E (0.54 g), the title compound was obtained as a ( yellow solid (0.39 g).
IR(Nujol)Vmax(cm-1)3279(NH,OH), 1703-1661 (C=O), 1630(C=C).
1H-NMR(DMSO) 12.41 (s), 9.39(s), 8.26(d), 7.48(d), 7.36(d), 7.27(d), 6.90(d), 6.80(d), 6.75(dd), 3.73(s), 2.19(s).
Example 2F (E) 3-f2-(2-Hvdfoxyphenylaminocarbonvnethenyl1-4.6-dichloroindole- 230 carboxylic acid
Starting from Example 1F (0.34 g), the title compound was obtained as a yellow-brown solid (0.33 g).
IR(Nujol)Vmax(cnr1)3150(NH,OH), 1736-1656(C=O), 1630(C=C). 1H-NMR(DMSO) 12.56(s), 9.97(s), 9.76(s), 8.24(s), 7.8(d), 7.49(d), 7.30(d),
6.96(d), 6.96(td), 6.88(dd), 6.79(td).
BAD ORIGINAL ft
Example 2G (E) 3-f2-(3.4-Dimethoxyphenylaminocarbonyhethenvll-4.6-dichloroindole-2carboxvlic acid
Starting from example 1G (0.41 g), the title compound was obtained as a light yellow solid (0.38g).
.IR(Nujol)Vmax(cm'1)3420-2381 (NH), 1690-1680(0=0), 1620-1607(C=C). IH-NMR(DMSO) 13.8-13.6(s), 12.53(s), 10.08(s), 8.23(d), 7.47(m), 7.29(d), 7.20(dd),6.89(d), 6.74(d), 3.37(s), 3.70(s).
Example 2H (E) 3-f2(4-Ethoxyphenylaminocafbonvl)ethenyn-4.6-dichloroindole-2-carboxylic acid IV
Starting from example 1H (0.25 g), the title compound was obtained as a light yellow solid (0.22 g).
IR(Nujol)nrnax(cm-1)3248(NH,OH), 1663(0=0), 1632-1610(0=0). IH-NMR(DMSO) 13.7(s), 12.50(s), 10.04(s), 8.22(d), 7.61(d), 7.47(d), 7.29(d), 6.86(d), 6.74(d), 3.97(q), 1.29(t).
Example 2I (E) 3-f2-(2.4-Difluorophenylaminocarbonyl)ethenyH-4.6-dichloroindole-2carboxvlic acid
Starting from example 11 (0.41 g), the title compound was obtained as a light yellow solid (0.37 g).
IR(Nujol)nmax(cnr1)3431-3233(NH,OH), 1707-1678(0=0), 1612(0=0). IH-NMR(DMSO) 14.0-13.6(s), 12.54(s), 9.99(s), 8.29(d), 7.97(m), 7.48(d), 7.30(m), 7.29(d), 7.07(m), 6.90(d).
Example 3
Methvl-3-i2-(phenvlcarbamoyDethvlnvn-4.6-dichlorindole-2-carboxvlate Intermediate 7 was dissolved in ethanol 95% (18 ml) then HCI (18 ml; 5 N) was added dropwise and the solution was refluxed for 3 hrs. After addition of ethyl acetate (50 ml) the two phases were separated and the organic layer washed with water (2 x 40 ml), dried and purified by chromatography. The white solid (140 mg) obtained was dissolved in THF (4 ml), water (2 ml) and stirred at room
BAD ORIGINAL A temperature for 10 minutes. After cooling to 8°, LiOHH2O (42 mg) was added, the obtained mixture was stirred for 1 h. then poured into a solution of 0.01 N HCI and extracted with ethyl acetate. The combined organic layers were dried and concentrated under reduced pressure to give a residue which was titurated in ether affording the title compound (100 mg) as a white solid.
Rf = 0.18 CE/EA: 70/30
IR(Nujol)Vmax(cm-1)3273(NH), 2220(C=C), 1686(C=C), 1636(C=O). IH-NMR(DMSO) 13.5(s), 10.71(s), 7.68(m), 7.52(m), 7.40(d), 7.35(m), 7.11(m), ‘ 3.96(s).
10
Example 4
3-f2-Phenvlcarbamovl)ethvnvn-4.6-dichloroindole2-carboxylic acid A mixture of Example 3 (100 mg) tetrahydrofuran (4 ml), water (2 ml) and LiOH· H2O (39 mg) was stirred at 45° for 12 hrs. Then, it was poured into water (15 ml) and HCI (0.05 M, 5 ml) was added dropwise under stirring. The obtained precipitate was collected by filtration to give the title compound as a yellow solid (63 mg,) m.p. = 207°
IR(Nujol)Vmax(cm*1) 3169(NH-OH), 2240(C=C), 1745(C=O), 1661 (C=O). IH-NMR(DMSO) 13.05(s), 14.0(s), 12.88(s),10.7(s), 7.67(d), 7.51(d),
7.35(d),7.33(m)( 7.10(m).
(
Example 5 ( (D.L.)-Trans-ethvl-3-f2-(2-phenylcarbamovl)cyclopropvn-4.6-dichloroindole-2carboxvlate (a) (D.L.1-Trans-ethvl-3-f2-(2-phenylcarbamoyhcvclopropyll-1-(2trimethvlsilvlethoxymethvl)-4.6-dichloroindole-2-carboxylate
To a mixture of Intermediate 8 (0.1 g.) and Palladium(ll)acetate (4 mg) in dichloromethane (10 ml) under nitrogen at 0°, a solution of diazomethane in diethyl ether (8 ml, 0.125M) was added with stirring. A black solid was obtained with effervescence. The reaction was stirred for 15 hours at room temperature then the solvent and any remaining diazomethane were evaporated under a flow of nitrogen. Dichloromethane was added to the resulting residue which was filtered through celite and evaporated under reduced pressure. Purification by
BAD ORIGINAL flash chromatography gave a mixture of starting material and title compound in ratio 0.3:1 (86 mg) as a pale yellow solid.
(b) (P.P-Trans-ethyl-S^-te-phenylcarbamovDcvcIopropyll^.edichloroindole-2-carboxvlate
HCI (2ml, 5M) was added to the product of Example 5a (66 mg) in ethyl alcohol (2 ml; 95%) and was stirred under reflux for 2 hours. After cooling, the mixture was poured into cold water (50 ml) and extracted with ethyl acetate (3 x 100 ml). The organic layers were combined, dried and the solvent was evaporated under reduced pressure to give the title compound (tic CH/EA = 6/4; Rf = 0.32).
IR (Nujol) V maxicm--1) 3312(NH), 1672(0=0), 1648 (C=O), 1599(C=C) 1535(0=0) 1H-NMR (CDCI3) 12.1 (s), 1O.2(S), 7.60(d), 7.40(d), 7.28(t), 7.01 (m), 4.40(m), 4.25(m), 2.55(m), 1.98(m), 1.49(m), 1.27(t), 1.22(m).
Example 6 (D.L.)-Trans-3-f2-phenvlcarbamoyl)cyclopropyll-4.6-diichloroindole-2-carboxylic acid
Starting from Example 5b (40 mg) and LiOH and using the general procedure of Example 2a the title compound was obtained as a white solid (23 mg).
IR (Nujol) V maxicm-1) 3271 (NH), 1663-1653(0=0), 1599 (C=C).
1H-NMR (DMSO) 13.4(s), 11.98(s), 10.11(s), 7.60(s), 7.37(d), 7.27(t), 7.17(d), 7.00(t), 1.97(m), 1.50(m), 1.47(m), 1.2(m).
Example 7
Ethyl-3-f(2-phenvlcarbamoyl)-propenyl1-4.6-dichloroindole -2-carboxylate
Intermediate 9 (660mg) was dissolved in 95% EtOH (6ml) and treated at reflux with 5N hydrochloric acid (6ml) overnight. The solution was then taken up with ethyl acetate, washed with 1N hydrochloric acid, water and brine dried filtered and concentrated. Purification by column chromatgoraphy yielded the title compound (220mg) as a white solid.
Rf= 0.30 CH/EA 7.5/2.5 1H-NMR (DMSO) 12.48(s,1H), 9.70(s,1H), 7.80-7.72(m,3H), 7.48(d,1H), 7.33(t,2H), 7.26(d,1H), 7.08(m,1H), 4.32(q,2H), 1.79(d,3H), 1.30(t,3H) ppm;
IR (nujol) (V max=cm·1) 3317-3288 (str NH), 1678 (str CO).
Example 8
3-ff2-Phenylcarbamovl)-propenvl1-4.6-dichloroindole -2-carboxvlic acid 5 Example 7 (210mg) was dissolved in 95% EtOH (6ml) and treated with LiOHH2O (32mg) at 30° for 1.5 days and then at room temperature for 2.5 days. Pie solution was then concentrated to dryness and treated for 2 hours with 1N hydrochloric acid. The white precipitate that formed was filtered, dried under high vacuum and then recrystallised from diethyl ethyl to give the title compound (135mg) as a white solid.
1H-NMR 13.5(s,1H), 12.37(s,1H), 9.70(s,1H), 7.76(d,2H), 7.75(s.1H),
7.45(d,1H), 7.31(t,2H), 7.23(d,1H), 7.06(t,1H), 1.78(d,3H)ppm.
IR (nujol) (Vrnax=cm*1) 3209(str, NH), 1664 (str, CO).
Example 9 (E) 3-f2-(phenvlcarbamoyl)ethenvn-4.6-dichloroindole-2-carboxvlic acid sodium salt
Methanol was added dropwise to a suspension of (E)3-[220 (phenylcarbamoyl)ethenyl]-4,6-dichloroindole-2-carboxylic acid 200mg in 0.5M soldium hydroxide (1.01 ml) until a clear solution was obtained. After 15 minutes of stirring, the solution was evaporated to dryness and the residue was dried at 50° for 12 hours to give the title compound as a white solid (150mg).
IR(nujol) Vmax(cm'1) 3404-3126-(NH), 1624(C=0),1600 (C=C).
1H-NMR (DMSO) 11,9(s), 10.06(s), 8.59(d), 7.75(d), 7.44(d), 7.27(t), 7.21(d), 7.10(d), 6.98(t).
Example 10 (E)-2-f-2-(N.N-diethylamino)ethyll)3-f2-(phenylaminocarbonvl)ethenvl1-4.630 dichloroindole-2-carboxvlate (E)Ethyl-3-[2-(phenylcarbamoyl)ethenyl]-4,6-dichloroindole-2-carboxylate (0.3g) and Ν,Ν-diethylethanolamine (1.3g) were stirred for 20 minutes before sodium carbonate (0.078g) was added and the mixture heated at 70θ for 24hrs. The solution was concentrated in vacuo and the residue left to stand overnight
BAD ORIGINAL ft resulting in a white precipitate. Filtration and crystallisation from ethyl acetate yelded the title compound (0.13g; Rf 0.65 = DCM/MeOH:8.2) as a white solid. IR(nujol) Vmax(cnr1) 3300 (NH), 1676(C=O),1624 (C=C).
1H-NMR (DMSO) 12.52(s), 10.18(s), 8.22(d), 7.70(d), 7.50(d), 7.32(d), 7.31 (t), 7.04(t), 6.73(d), 4.36(t), 2.75(t), 2.49(q), 0.90(t).
Example 11 (El 2-f4-f-2lN-morpholino)ethyl13-f2-fphenylaminocarbonvl)ethenvn-4.6dichloroindole-2-carboxvlate
A mixture of (E)Ethyl-3-[2-(phenylcarbamoyl)ethenyl]-4,6-dichloroindole-2carboxylate (400mg), 4-(2-hydroxyethyl)morpholine (7ml) and p-toluensulphonic acid (15mg) was stirred at 130° for 120hrs.The mixture was, diluted with water and extracted with ethyl acetate (3 x 100ml). The organic extracts were dried, concentrated and the precipitate collected to give the title compound as a white solid (110mg Rf 0.51 = DCM/MeOH: 9/1, m.p=266-267°).
1H-NMR (DMSO) 10.21 (s), 8.28(d), 7.75(d), 7.56-7.35(d,d), 7.35(f), 7.08(f), 6.74(d), 4.46(f), 3.54(m), 2.43(m), 2.70(t).
Example 12 (a) (E)-2-(t-Butylcarbonyloxvmethvh3-f2-(phenylaminocarbonyBethenyl1-4.6dichloroindole-2-carboxvlate
Example 2 (200mg) was dissolved in DMF (4ml) and tetrabutylammonium chloride (168mg) was added. After stirring 0.5h.p chloromethylpivalate (118mg) was added dropwise and the reaction was stirred at room temperature for 48hrs. The mixture was diluted with water and extracted with ethyl acetate (2 x 100ml). The organic layer was washed with brine, dried and evaporated to give a crude product that was purified by flash chromatography to give the title compound as a yellow solid (190mg) m.p. = 205°.
IR(nujol) Vmax(crTT1) . 3383-3308 (NH), 1747 (C=O), 1688 (C=O), 16341603(0=0).
1H-NMR (DMSO) 12.75(s), 10.22(s), 8.22(d), 7.73(d), 7.54(d), 7.36(d), 7.33(t), 7.07(f), 6.79(d), 6.02(s), 1.15(s).
Using the same, general procedure the following compound were prepared:
BAD ORIGINAL ft (b) (E)-2-f1 -(Tetrahydro-4-pvran-4-vloxvcarbonvloxv)ethyn3-f2fphenylaminocarbonvnethenvn-4.6-dichloroindole-2-carboxvlate
From Example 2 (200mg) in dry DMF (11 ml), benzyltriethylylammonium chloride (178mg) and 1-(tetrahydro-4-H-pyran-4-yloxycarbonyloxy)ethyl chloride (244mg), after 4 days of stirring at room temperature the title compound was obtained as a yellow solid (209mg). m.p. = 209°.
IR(nujol) Vmax(cm-1) 3300 (NH), 1749 (C=O), 1730 (C=O), 1H-NMR (DMSO) 12.73(s), 10.22(s), 8.21(d), 7.72(d), 7.53(d), 7.34(d), 7.32(t), 7.05(t), 6.90lq), 6.76(d), 4.76(m), 3.72(m), 1.87-1.53(m), 1.61(d).
(c) (E)-2[1-(Cvclohexvloxvcarbonvloxv)ethvn3-f2(phenylaminocarbonv0ethenvl1-4.6-dichloroindole-2-carboxvlate From Example 2 (300mg) in dry DMF (8ml), benzyltriethylammonium chloride (178mg) and 1-(cydohexyloxycarbonyloxy)ethyl chloride (242mg), after 0.5hrs of stirring at room temperature, the title compound was obtained as a yellow solid (170mg) m.p. = 125°·
IR(nujol) Vmax(cm-1) 3300 (NH), 1730 (C=O).
1H-NMR (DMSO) 12.71 (sO, 10.21 (s), 8.21(d), 7.71(d), 7.51(d), 7.36-7.26(m), 7.05(t), 6.85(q), 6.76(d), 4.54(m), 1.79(m), 1.51-1.1(m), 1.6(d).
(d) (E)-2f(Methoxvcarbonvlmethvn3-f2-(phenvlaminocarbonynethenyn-4.6dichloroindole-2-carboxylate
From Example 2 (200mg) in dry DMF (4ml), tetrabutylammonium chloride (168mg) and methyl chloroacetate (85mg), after 48hrs of stirring at room temperature, the title compound was obtained as an off-white solid (210mg). m.p. = 241-242°.
IR(nujol) Vmax(cm-1) 3348(NH), 1749(0=0), 1672(0=0), 1634-1610(0=0). 1H-NMR (DMSO) 12.8(s), 10.21 (s), 8.28(d), 7.72(d), 7.54(d), 7.38-7.28(m), 7.06(t), 6.48(d). 5.02(s), 3.73(s).
Pharmacy Examples
A. Capsules/ Tablets
Active ingredient Starch 1500
200. Omg 32.5mg
BAD ORIGINAL
Microcrystalline Cellulose Croscarmellose Sodium Magnesium Stearate
60.0mg
6.0mg
1.5mg
The active ingredient is blended with the other excipients. The blend can be used to fill gelatine capsules or compressed to form tablets using appropriate punches. The tablets can be coated using conventional technqiues and coatings.
B. Tablet
Active ingredient 200. Omg
Lactose lOO.Omg
Macrocrystalline Cellulose 28.5mg
Povidone 25. Omg
Croscarmellose Sodium 6.0mg
Magnesium Stearate 1.5mg
The active ingredient is blended with lactose, microcrystalline cellulose and part of the croscarmellose sodium. The blend is granulated with povidone after dispersing in a suitable solvent (i.e. water). The granule, after drying and comminution is blended with the remaining excipients. The blend can be compressed using appropriate punches and the tablets coated using conventional techniques and coatings.
C. Injection Formulation
Active ingredient 0.1 - 7.00mg/ml
Sodium phosphate 1.0 - 50.00mg/ml
NaOH qs desidered pH (range 3-10) water for injection qs to 1 ml
The formulation may be packed in glass (ampoules) with a rubber stopper (vials,
D. Dry Powder for constitution with a suitable vehicle
Active ingredient: 0.1 - 100.00mg
Mannitol qs to 0.02 - 5.00mg packed in glass vials or syringes,with a rubber stopper and (vials only) a plastic metal overseal.
E, Inhalation Cartridges mg/cartridge
Active ingredient (micronised) 5.00
Lactose to 25.00
The active ingredient is micronised in a fluid energy mill to a fine particle size range prior to blending with normal tabletting grade lactose in a high energy mixer. The powder blend is filled into a proper unit dose container as blister or capsule for use in a suitable inhalation or insufflation device.
The affinity of the compound of the invention for strychnine insensitvie glycine binding site was determined using the procedure of Kishimoto H. et al J. Neurochem 1981, 37.1015-1024. The pKi values obtained with respresentative compounds of the invention are given in the following table.
BAD ORIGINAL ft
Example No. pKi
2a 8.5
2f 8.4
2g 8.1
2h 8.3
2i 8.3
2j 8.0
4 7.7
8 8.32
The ability of compounds of the invention to inhibit NMDA included convulsions in the mouse was determined using the procedure of Chiamulera C et al. Psychopharmacology 1990, 102, 551-552. In this test the ability of the compound to inhibit the generalized seizures induced .by an intracerebroventricular injection of NMDA in mice was examined at a number of dose levels. From these results the dose required to protect 50% of the animals from the convulsive action of the NMDA was calculated,.This expressed as mg/kg is referred to as the ED^ value.
Representative results obtained for compounds of the invention when given by intravenous and oral administration are given in the following table.
Ex No. ed50 iv mg/kg po
1a 0.7 0.3-1
4 0.43 3
9 0.6 5.98
11 0.3 3.2
12 0.3 10
BAD ORIGINAL
The compounds of the invention are essentially non toxic at therapeutically use ful doses. Thus for example the compound of Example 9 produced no untoward side effects when administered to rats and mice at doses of 3-30mg/kg iv or 30-300mg/kg orally.

Claims (3)

  1. Claims
    1. A compound of formula (1)
    kxkr COjH Pi / h (I) or a physiologically acceptable salt, or metabolically labile ester thereof
    wherein R represents a group selected from halogen, alkyl, alkoxy, amino, 10 alkylamino, dialkylamino, hydroxy, trifluoromethyl, trifluoromethoxy, nitro, cyano,
    SO2R1 or COR1 wherein R-j represents hydroxy, methoxy, or amino; m is zero or an integer 1 or 2;
    A represents an ethynyl group or an optionally substituted ethenyl, or cyclopropyl group;
    15 X represents NH;
    R2 represents an aryl group.
    2. A compound as claimed in Claim 1 wherein m is 2 and R is chlorine at the 4 and 6 positions in the indole nucleus.
    3. A compound as claimed in Claims 1 to 3 wherein R2 is an optionally substituted phenyl group.
    4. A compound as claimed in any of Claims 1 to 3 wherein R2 is phenyl. 25
    5. A compound as claimed in any of Claims 1 to 4 wherein A is ethynyl, optionally substituted cyclopropyl or substituted ethenyl.
    6. A compound as claimed in any of Claims 1 to 5 wherein A is ethynyl or
    30 1-methylethenyl in the trans configuration.
    BAD ORIGINAL r * ·
    CH178
    7. A compound as claimed in any of claims 1 to 6 wherein A is an unsubstituted ethenyl group.
    8. A compound as claimed in Claim 7 wherein the unsubstituted ethenyl 5 group is in the trans configuration and R2 is a phenyl group substituted by one or two groups selected from fluorine, trifluromethyl, methyl, isopropyl, hydroxy, methoxy, ethoxy or nitro.
    9. (E)-3-(2(-phenylcarbamoyl))ethenyl)-4,6-dichloroindole-2- carboxylic 10 acid; and physiologically acceptable salts thereof and metabolically labile esters thereof.
    10. (E)-3-[2-phenylcarbamoylpropenyl]-4,6-dichloroindole-2 - carboxylic acid; and physiologically acceptable salts and metabolically labile esters
    15 thereof.
    11. (E)-3-[2(Phenylcarbamoyl)ethynyI)-4,6-dichloroindole -2- carboxylic acid; and physiologically acceptable salts and metabolically labile esters thereof.
    12. The compounds:
    (EJ-S-p-^-ethoxyphenylcarbamoyOethenylH.e-dichloroindole^- carboxylic acid;
    25 (E)-3-[2-(2-hydroxy-5-nitrophenylcarbamoyl)ethenyl)-4,6-dichloroindole-2 carboxylic acid;
    (E)-3-[2-(2-methyl-4-methoxyphenylcarbamoyl)ethenyl)-4,6- dichloroindole-2carboxylic acid;
    (E)-3-[2-(2-isopropylphenylcarbamoyl)ethenyl)-4,6-dichloroindole -2- carboxylic 30 acid;
    (E)-3-(2-(2,4-difluorophenylcarbamoyl)ethenyl)-4,6- dichloroindole-2-carboxyIic acid;
    (E)-3-f2-(3,4-dimethoxyphenylcarbamoyl)ethenyl)-4,6-dichloroindole-2carboxylic acid; and physiologically acceptable salts and metabolically labile
    35 esters thereof.
    BAD ORIGINAL £
    CH178
    13. Compounds as claimed in any of Claims 1 to 12 for use in therapy.
    14. The use of a compound as claimed in any of claims 1 to 12 in the manufacture of a therapeutic agent for antagonising the effects of excitatory amino acids on the NMDA receptor complex.
    15. A pharmaceutical composition comprising a compound in any of Claims 1 to 12 in admixture with one or more physiologically acceptable carriers or excipients.
    16. A process for preparing the compounds as defined in Claim 1 which comprises:
    (a) reacting the indole (II) in which R1( R3, R4 and m have the meanings defined in Claim 1 (IO with an appropriate phosphorus ylide to introduce the group ACOXR2 wherein X and R2 have the meanings defined in Claim 1 and A is an optionally substituted ethenyl group.
    (b) reacting an olefin of formula (V)
    N^CHCOXRj (vn wherein R1( R3. R4 and m have the meanings defined above and R6 and R8 independently represent hydrogen or C^aikyl with the diazo derivative (Vi) wherein X and R2 have the meanings defined in Claim 1 to produce a compound of formula (I) wherein A is an optionally substituted cyclopropyl group.
    (c) reacting a compound of formula (VII) wherein R, m, X and R2 have the meanings defined above and Rg is a trimethylsilylethoxymethyl group
    BAD ORIGINAL ft
    CH178 with hydrochloric acid followed by treatment with a base to give a compound of 5 formula (I) wherein A is an ethynyl group;
    and thereafter is necessary or desired followed by one or more of the following ( operations.
    (1) removal of the carboxyl protecting group.
  2. (2) conversion of the resultant compound of formula (I) or a carboxyl protected 10 derivative thereof into a salt or metabolically labile ester thereof.
  3. (3) conversion of one compound of formula (I) or a protected derivative thereof into another compound of formula (1) or a protected derivative thereof.
APAP/P/1993/000524A 1992-04-16 1993-04-16 3-Substituted indole 2-carboxylic acid derivatives. AP480A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929208492A GB9208492D0 (en) 1992-04-16 1992-04-16 Heterocyclic compounds

Publications (2)

Publication Number Publication Date
AP9300524A0 AP9300524A0 (en) 1993-04-30
AP480A true AP480A (en) 1996-03-22

Family

ID=10714220

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1993/000524A AP480A (en) 1992-04-16 1993-04-16 3-Substituted indole 2-carboxylic acid derivatives.

Country Status (41)

Country Link
US (4) US5374649A (en)
EP (1) EP0568136A1 (en)
JP (2) JPH07505407A (en)
KR (1) KR100264114B1 (en)
CN (1) CN1042331C (en)
AP (1) AP480A (en)
AT (1) AT403917B (en)
AU (1) AU666927B2 (en)
BE (1) BE1006343A5 (en)
BG (1) BG62136B1 (en)
BR (1) BR1100323A (en)
CA (3) CA2094076A1 (en)
CH (1) CH685630A5 (en)
CY (1) CY2038B1 (en)
CZ (1) CZ285799B6 (en)
DK (1) DK169890B1 (en)
ES (1) ES2105924B1 (en)
FI (1) FI106198B (en)
FR (1) FR2690919B1 (en)
GB (2) GB9208492D0 (en)
GE (1) GEP19991704B (en)
GR (1) GR1001619B (en)
HK (1) HK95797A (en)
HU (2) HU217964B (en)
IL (1) IL105412A (en)
IS (1) IS3994A (en)
IT (1) IT1265325B1 (en)
LU (1) LU88248A1 (en)
MX (1) MX9302195A (en)
MY (1) MY112232A (en)
NO (1) NO301879B1 (en)
NZ (1) NZ247413A (en)
OA (1) OA10103A (en)
PL (1) PL176451B1 (en)
RO (1) RO113242B1 (en)
RU (1) RU2129544C1 (en)
SE (1) SE504336C2 (en)
SK (1) SK281941B6 (en)
TW (1) TW224457B (en)
WO (1) WO1993021153A1 (en)
ZA (1) ZA932642B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
CN1051302C (en) * 1993-05-27 2000-04-12 默里尔药物公司 3-(indol-3-yL) propenoic acid derivatives and as NMDA antagonists
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
TW280819B (en) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5563157B1 (en) * 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
WO1998011892A1 (en) * 1996-09-17 1998-03-26 The Regents Of The University Of California Positive ampa receptor modulation to enhance brain neurotrophic factor expression
WO1998014427A1 (en) * 1996-09-30 1998-04-09 Hoechst Marion Roussel, Inc. Nmda (n-methyl-d-aspartate) antagonists
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
DK2198858T3 (en) * 1998-03-26 2011-10-03 Astellas Pharma Inc Sustained release preparation of a macrolide compound such as tacrolimus
US20030162825A1 (en) * 2001-11-09 2003-08-28 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
MXPA04005427A (en) * 2001-12-10 2005-04-19 Amgen Inc Vanilloid receptor ligands and their use in treatments.
PA8579701A1 (en) * 2002-08-23 2005-05-24 Pfizer Prod Inc BETA-LACTAMASA INHIBITOR PROFARMACO
DE10306202A1 (en) 2003-02-13 2004-08-26 Grünenthal GmbH 2-(hetero)aryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or especially pain is NMDA antagonist
WO2004108733A1 (en) * 2003-06-05 2004-12-16 Pfizer Products Inc. Beta-lactamase inhibitor prodrug
JP4864719B2 (en) * 2003-11-26 2012-02-01 ファイザー・プロダクツ・インク Aminopyrazole derivatives as GSK-3 inhibitors
EP1709004A2 (en) * 2003-12-29 2006-10-11 Sepracor Inc. Pyrrole and pyrazole daao inhibitors
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP2009500425A (en) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド Eszopiclone and trans 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine or trans 4- (3,4-dichlorophenyl) -1,2,3 4-Tetrahydro-1-naphthalenamine combinations and methods for treating menopause and mood, anxiety, and cognitive impairment
KR101381768B1 (en) * 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 Tetralone-based monoamine reuptake inhibitors
AU2007205114B2 (en) * 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
CN103588659A (en) 2006-03-31 2014-02-19 赛诺维信制药公司 Preparation of chiral amides and amines
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
BRPI0806604A2 (en) * 2007-01-18 2011-09-06 Sepracor Inc d-amino acid oxidase inhibitors
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
MX2009012685A (en) 2007-05-31 2009-12-14 Sepracor Inc Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors.
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
CA2755118A1 (en) * 2009-03-10 2010-09-16 Santen Pharmaceutical Co., Ltd. Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2015253099B2 (en) 2014-04-30 2019-07-18 National Chiao Tung University Use of known compounds as D-amino acid oxidase inhibitors
KR20220084439A (en) 2016-09-14 2022-06-21 위펑 제인 쳉 Novel substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors
CA3067162A1 (en) 2017-06-12 2018-12-20 Glytech Llc. Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists
CN112707874A (en) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 Antiviral compound and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
EP0396124A2 (en) * 1989-05-05 1990-11-07 G.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK500285A (en) * 1984-11-02 1986-05-03 Glaxo Group Ltd cephalosporin antibiotics
CA2087091C (en) * 1990-07-16 2001-09-11 Francesco G. Salituro Excitatory amino acid antagonists
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
EP0396124A2 (en) * 1989-05-05 1990-11-07 G.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders

Also Published As

Publication number Publication date
IL105412A0 (en) 1993-08-18
CA2094076A1 (en) 1993-10-17
ATA75293A (en) 1997-11-15
CY2038B1 (en) 1998-04-30
GB9307808D0 (en) 1993-06-02
CN1085212A (en) 1994-04-13
ITRM930236A1 (en) 1994-10-15
ES2105924A1 (en) 1997-10-16
GB2266091A (en) 1993-10-20
FI944800A0 (en) 1994-10-12
HK95797A (en) 1997-08-08
US5374648A (en) 1994-12-20
ITRM930236A0 (en) 1993-04-15
NO943913D0 (en) 1994-10-14
CN1042331C (en) 1999-03-03
CH685630A5 (en) 1995-08-31
US5373018A (en) 1994-12-13
GR1001619B (en) 1994-07-29
TW224457B (en) 1994-06-01
GEP19991704B (en) 1999-08-05
MX9302195A (en) 1994-03-31
HUT70526A (en) 1995-10-30
RO113242B1 (en) 1998-05-29
ES2105924B1 (en) 1998-07-01
AP9300524A0 (en) 1993-04-30
RU94045915A (en) 1996-09-10
BR1100323A (en) 2000-06-27
HU9402975D0 (en) 1995-02-28
FR2690919B1 (en) 1995-05-05
FI106198B (en) 2000-12-15
AU666927B2 (en) 1996-02-29
WO1993021153A1 (en) 1993-10-28
SK281941B6 (en) 2001-09-11
EP0568136A1 (en) 1993-11-03
DK169890B1 (en) 1995-03-27
CZ254394A3 (en) 1995-07-12
NO943913L (en) 1994-12-14
NZ247413A (en) 1995-12-21
JPH07505407A (en) 1995-06-15
KR100264114B1 (en) 2000-11-01
SE9301241D0 (en) 1993-04-15
SE9301241L (en) 1993-10-17
GB2266091B (en) 1995-08-09
BG62136B1 (en) 1999-03-31
JPH0649027A (en) 1994-02-22
OA10103A (en) 1996-12-18
FI944800A (en) 1994-10-12
BE1006343A5 (en) 1994-07-26
IS3994A (en) 1993-10-17
IT1265325B1 (en) 1996-10-31
NO301879B1 (en) 1997-12-22
HU217964B (en) 2000-05-28
MY112232A (en) 2001-05-31
DK43193A (en) 1993-10-17
IL105412A (en) 1998-02-22
CA2094073A1 (en) 1993-10-17
HU211826A9 (en) 1995-12-28
US5374649A (en) 1994-12-20
RU2129544C1 (en) 1999-04-27
ZA932642B (en) 1994-01-10
BG99111A (en) 1995-05-31
GB9208492D0 (en) 1992-06-03
CA2094075A1 (en) 1993-10-17
LU88248A1 (en) 1994-03-01
SE504336C2 (en) 1997-01-13
SK124194A3 (en) 1995-05-10
CZ285799B6 (en) 1999-11-17
US5510367A (en) 1996-04-23
PL176451B1 (en) 1999-05-31
FR2690919A1 (en) 1993-11-12
AT403917B (en) 1998-06-25
AU3692393A (en) 1993-10-21
DK43193D0 (en) 1993-04-15

Similar Documents

Publication Publication Date Title
AP480A (en) 3-Substituted indole 2-carboxylic acid derivatives.
US5686461A (en) Indole derivatives
US5962496A (en) Indole derivatives as NMDA antagonists
AP877A (en) Tetrahydroquinoline derivatives as EAA antagonists.
US5977136A (en) Tetrahydroquinolines as NMDA antagonists
KR19980702735A (en) Indole derivatives as EAA antagonists
EP0971896A1 (en) Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
WO1995007887A1 (en) Indole derivatives as antagonists of excitatory amino acids
CZ340599A3 (en) Derivative of quinoline-2-carboxylic acid